Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired β-cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study.
Bianchi C, Miccoli R, Trombetta M, Giorgino F, Frontoni S, Faloia E, Marchesini G, Dolci MA, Cavalot F, Cavallo G, Leonetti F, Bonadonna RC, Del Prato S; GENFIEV Investigators. Bianchi C, et al. Among authors: bonadonna rc. J Clin Endocrinol Metab. 2013 May;98(5):2100-5. doi: 10.1210/jc.2012-3971. Epub 2013 Mar 28. J Clin Endocrinol Metab. 2013. PMID: 23539736 Clinical Trial.
Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials.
Raccah D, Lin J, Wang E, Germé M, Perfetti R, Bonadonna RC, de Pablos-Velasco P, Roussel R, Rosenstock J. Raccah D, et al. Among authors: bonadonna rc. J Diabetes Complications. 2014 Jan-Feb;28(1):40-4. doi: 10.1016/j.jdiacomp.2013.10.003. Epub 2013 Oct 14. J Diabetes Complications. 2014. PMID: 24246441
Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists.
Giorgino F, Bonadonna RC, Gentile S, Vettor R, Pozzilli P. Giorgino F, et al. Among authors: bonadonna rc. Diabetes Metab Res Rev. 2016 Sep;32(6):497-511. doi: 10.1002/dmrr.2775. Epub 2016 Mar 30. Diabetes Metab Res Rev. 2016. PMID: 26787264 Free PMC article. Review.
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial.
Wysham C, Bonadonna RC, Aroda VR, Puig Domingo M, Kapitza C, Stager W, Yu C, Niemoeller E, Souhami E, Bergenstal RM; LixiLan-L trial investigators. Wysham C, et al. Among authors: bonadonna rc. Diabetes Obes Metab. 2017 Oct;19(10):1408-1415. doi: 10.1111/dom.12961. Epub 2017 Jun 8. Diabetes Obes Metab. 2017. PMID: 28386990 Free PMC article. Clinical Trial.
Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.
Santilli F, Simeone PG, Guagnano MT, Leo M, Maccarone MT, Di Castelnuovo A, Sborgia C, Bonadonna RC, Angelucci E, Federico V, Cianfarani S, Manzoli L, Davì G, Tartaro A, Consoli A. Santilli F, et al. Among authors: bonadonna rc. Diabetes Care. 2017 Nov;40(11):1556-1564. doi: 10.2337/dc17-0589. Epub 2017 Sep 14. Diabetes Care. 2017. PMID: 28912305 Clinical Trial.
209 results